ArticleJournal of applied clinical medical physics2026
Assessment of 6MV flattening filter free (FFF) beam commissioning parameters for Versa HD and TrueBeam: A comparison study.
Article in Journal of applied clinical medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFlattening filter-free (FFF) beams are increasingly deployed for stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS). The Elekta Versa HD (VHD) and Varian TrueBeam (TB) are the two most widely used FFF-capable platforms; however, no prior study has compared their 6 MV FFF commissioning parameters under fully equipment-equivalent conditions. PURPOSE: To quantify the dosimetric differences between the Elekta VHD and Varian TB 6 MV FFF platforms under equipment-equivalent conditions and to assess their translation into patient treatment plan parameters.
methodsPercentage depth doses (PDDs), lateral beam profiles, and output factors (OFs) were acquired using an identical-model IBA SMARTSCAN three-dimensional water tank, a unified detector set (IBA RAZOR for small fields; CC13 for standard fields), and a fixed source-to-surface distance of 90 cm for both platforms, in conformance with AAPM TG-45, AAPM TG-106, and IAEA TRS-483. A treatment planning translation study was performed in the Monaco TPS using the IBA IMRT phantom, with 3D-CRT plans generated for four spherical targets (1, 3, 6, and 12 cm diameter) on both beam models.
resultsVHD demonstrated consistently deeper beam penetration, with R50 exceeding TB by a mean of 1.753 ± 0.048 cm across all field sizes (t(9) = 36.34, p < 0.001, Cohen's d = 11.49, 95% CI [1.643, 1.862] cm). TB delivered significantly higher surface doses than VHD (mean Ds: 63.64 ± 5.77% vs. 48.78 ± 7.72%; p = 0.002, |r| = 1.000). At 10 cm depth, VHD showed a higher percentage depth dose (mean difference = 5.005 ± 0.352%; t(9) = 14.22, p < 0.001, d = 4.498). The Unflatness conversion index (UCI) was strongly correlated with field size (r = 0.916, p = 0.001) and statistically independent of measurement depth (p = 0.292). At the plan level, TB required 5.9-17.6% more monitor units (MU) than VHD across all target sizes, with the differential diminishing as target diameter increased. Surface dose differences were preserved across all four targets (TB - VHD: 15.9-31.1%). Both the homogeneity index and gradient index reversed direction between the 1 cm target (VHD superior) and targets of 3 cm and larger (TB superior), consistent with the field-size dependence of UCI.
conclusionA harmonized, equipment-equivalent measurement approach demonstrated systematic differences between VHD and TB FFF beams in penetration, surface dose, and field-size-dependent unflatness. Treatment planning study across four target sizes (1-12 cm) showed these differences propagate to plan-level parameters in a target-size-dependent manner, with VHD advantageous for small targets and TB for larger ones. The UCI, depth-independent and strongly correlated with field size (r = 0.916), provides a simple cross-platform unflatness comparison tool supporting machine-specific planning strategies in multi-platform clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.